Limited coverage criteria – interferon alfa

Last updated on March 18, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Learn more or log in

Return to Special Authority drug list

Generic name	interferon alfa-2B (Intron A®)
Strength & form	10,000,000 IU/vial 6,000,000 IU/mL 10,000,000 IU/mL 15,000,000 IU/mL 25,000,000 IU/mL 50,000,000 IU/mL subcutaneous injection

Generic name

interferon alfa-2B (Intron A®)

Strength & form

10,000,000 IU/vial
6,000,000 IU/mL
10,000,000 IU/mL
15,000,000 IU/mL
25,000,000 IU/mL
50,000,000 IU/mL

subcutaneous injection

Special Authority criteria	Approval period
For the diagnosis of chronic hepatitis B, non-cirrhosis, according to established protocols Lab work is required	First approval: 24 weeks One renewal: Up to 24 weeks, only if patient demonstrates a positive response to treatment

Special Authority criteria

Approval period

For the diagnosis of chronic hepatitis B, non-cirrhosis, according to established protocols

Lab work is required

First approval: 24 weeks

One renewal: Up to 24 weeks, only if patient demonstrates a positive response to treatment

Practitioner exemptions

None

Special notes

In exceptional cases, PharmaCare may consider requests for coverage of patients who do not meet the established criteria if the physician provides additional documentation supporting the patient’s specific clinical need
The Hepatitis Drug Benefit Adjudication Advisory Committee reviews exceptional case submissions

Special Authority request form(s)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics